P023 Real-world melanoma miss rate in an NHS hospital dermatology service

Hafsa Faarax Shirwac,Hannah Morgan,Huw Greenish,Sarah Carswell,Harry Heath,James Koutsis,Pascale Guitera,Alexander D G Anderson

DOI: https://doi.org/10.1093/bjd/ljae090.050

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract The aim of this retrospective study was to assess the ‘miss rate’ of dermatology clinicians for detecting malignant melanoma among patients referred on the 2-week-wait skin cancer pathway over a 2-year period. We reviewed patient records from the previous 5 years to identify instances where malignant melanoma might have been misdiagnosed. Malignant melanoma can be missed at various stages of the patient’s journey, leading to delayed diagnosis and potentially serious consequences. Our geographically isolated rural county relies exclusively on a single NHS dermatology department for 2-week-wait skin cancer services, providing a unique opportunity to assess the incidence of missed melanoma. We used a regional cancer registry to identify all primary invasive malignant melanomas (ICD-10 C43) diagnosed between August 2020 and July 2022. Records of any patient who had attended the dermatology department within the 5 years preceding diagnosis were reviewed to identify patients where melanoma might have been previously misdiagnosed. In total, 432 primary melanomas were identified. The male-to-female ratio was 202 : 230 and the median age was 71 years (interquartile range 57–79). Stage at presentation was IA (176, 40.7%), IB (98, 22.7%), II (134, 31.0%), III (19, 4.4%) and IV (5, 1.2%). Nine patients (2.1%) had been given an erroneous benign diagnosis for the same lesion and discharged within 13 months of diagnosis (missed melanoma). The stages of the missed melanomas were IA (two patients), IB (four patients) and II (three patients). In a further four cases (0.9%) the melanoma had prompted action, but the diagnosis was delayed; one had an erroneous negative biopsy, one missed an urgent review, one lesion was monitored, leading to a 6-month delay in diagnosis, and one was incorrectly diagnosed as a basal cell carcinoma, leading to a delay in surgery. A final four (0.9%) cases were diagnosed as benign more than 2 years prior to melanoma diagnosis. These were classified as ‘possible’ misses, as they could have evolved into malignant melanomas in the interim period. Our study reveals a low yet quantifiable melanoma miss rate in a high-volume NHS dermatology service. Future multicentre studies with large datasets are required, to identify risk factors for misdiagnosis. Clinicians managing skin lesion clinics may consider melanoma miss rate as a key performance metric. Strategies to improve the accuracy of this important metric might include the use of prospective databases incorporating digital images of lesions suspected to be benign. The utility of this approach should be investigated further.

dermatology